Open Access
Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non-Small Cell Lung Cancer
Mark G. Kris,Ronald B. Natale,Roy S. Herbst,Diane Prager,Chandra P. Belani,Joan H. Schiller,Karen Kelly,Harris Spiridonidis,Alan B. Sandler,Kathy S. Albain,David Cella,Michael K. Wolf,Steven D. Averbuch,Judith Ochs,Andrea C. Kay +14 more
Reads0
Chats0
TLDR
Gefitinib, a well-tolerated oral EGFR-tyrosine kinase inhibitor, improved disease-related symptoms and induced radiographic tumor regressions in patients with NSCLC persisting after chemotherapy as mentioned in this paper.Abstract:
Results Of 221 patients enrolled, 216 received gefitinib as randomized. Symptoms of NSCLC improved in 43% (95% confidence interval [CI], 33%-53%) of patients receiving 250 mg of gefitinib and in 35% (95% CI, 26%-45%) of patients receiving 500 mg. These benefits were observed within 3 weeks in 75% of patients. Partial radiographic responses occurred in 12% (95% CI, 6%-20%) of individuals receiving 250 mg of gefitinib and in 9% (95% CI, 4%-16%) of those receiving 500 mg. Symptoms improved in 96% of patients with partial radiographic responses. The overall survival at 1 year was 25%. There were no significant differences between the 250-mg and 500-mg doses in rates of symptom improvement (P=.26), radiographic tumor regression (P=.51), and projected 1-year survival (P=.54). The 500-mg dose was associated more frequently with transient acne-like rash (P=.04) and diarrhea (P=.006). Conclusions Gefitinib, a well-tolerated oral EGFR-tyrosine kinase inhibitor, improved disease-related symptoms and induced radiographic tumor regressions in patients with NSCLC persisting after chemotherapy.read more
Citations
More filters
Journal ArticleDOI
Summary Statement: Novel Agents in the Treatment of Lung Cancer: Advances in Epidermal Growth Factor Receptor-Targeted Agents
Thomas J. Lynch,Alex A. Adjei,Paul A. Bunn,Tim Eisen,Jeffrey A. Engelman,Glenwood D. Goss,Daniel A. Haber,John V. Heymach,Pasi A. Jänne,Bruce E. Johnson,David H. Johnson,Rogerio Lilenbaum,Matthew Meyerson,Alan B. Sandler,Lecia V. Sequist,Jeffrey Settleman,Kwok-Kin Wong,Carol S. Hart +17 more
TL;DR: The Third Cambridge Conference on Novel Agents in the Treatment of Lung Cancer was convened in Cambridge, Massachusetts on September 23 to 24, 2005 to discuss ongoing research into the significance of the epidermal growth factor receptor (EGFR) pathway in the biology of non–small cell lung cancer.
Journal ArticleDOI
Germline Polymorphisms in EGFR and Survival in Patients With Lung Cancer Receiving Gefitinib
Vanesa Gregorc,Manuel Hidalgo,Adriano Spreafico,G Cusatis,Vienna Ludovini,Roxann G. Ingersoll,Sharon Marsh,SM Steinberg,M. G. Vigano,D Ghio,Eugenio Villa,Alex Sparreboom,Sharyn D. Baker +12 more
TL;DR: The results may help identify patients with non‐small‐cell lung cancer who can benefit from gefitinib treatment and may help identifying patients with NSCLC who canBenefit from gEFit inib treatment.
Journal ArticleDOI
Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: A chromogenic in situ hybridization study of 182 patients
John Wen-Cheng Chang,Hui-Ping Liu,Meng-Heng Hsieh,Yueh-Fu Fang,Meng-Shu Hsieh,Jia-Juan Hsieh,Yu-Ting Chiu,Hsien-Yu Tsai,Yi-Hsuan Chen,Ya-Ting Chen,Hui-Yu Hsu,Ying-Tsong Chen,Shih-Feng Tsai,Yi-Rong Chen,Bae-Li Hsi,Shiu-Feng Huang +15 more
TL;DR: Increased EGFR copy number was highly correlated with EGFR mutation in adenocarcinoma and could be a good alternative molecular predictive marker for TKI responsiveness, since CISH can be done on paraffin section and is much quicker than DNA sequencing.
Journal ArticleDOI
Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non-small cell lung cancer: A phase II study.
TL;DR: Neoadjuvant therapy with gefitinib in patients with stage II-IIIA NSCLC is safe and may be a viable treatment for patients whose tumors have EGFR mutations.
Journal ArticleDOI
Challenges in the Development of Anti-Epidermal Growth Factor Receptor Therapies in Breast Cancer
TL;DR: A point of view regarding challenges in the development of anti-EGFR therapies for patients with breast cancer and possible approaches to overcome them is presented in this article.
References
More filters
Book
Statistical methods for rates and proportions
TL;DR: In this paper, the basic theory of Maximum Likelihood Estimation (MLE) is used to detect a difference between two different proportions of a given proportion in a single proportion.
Journal ArticleDOI
Statistical Methods for Rates and Proportions.
B. S. Everitt,Joseph L. Fleiss +1 more
Journal ArticleDOI
The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.
David Cella,David S. Tulsky,G Gray,Bernie Sarafian,E Linn,Amy E. Bonomi,M Silberman,Suzanne B. Yellen,Patsy Winicour,J Brannon +9 more
TL;DR: The FACT-G meets or exceeds all requirements for use in oncology clinical trials, including ease of administration, brevity, reliability, validity, and responsiveness to clinical change.
Journal ArticleDOI
Revisions in the International System for Staging Lung Cancer
TL;DR: Analysis of a collected database representing all clinical, surgical-pathologic, and follow-up information for 5,319 patients treated for primary lung cancer confirmed the validity of the TNM and stage grouping classification schema.
Journal ArticleDOI
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Masahiro Fukuoka,Seiji Yano,Giuseppe Giaccone,Tomohide Tamura,Kazuhiko Nakagawa,Jean-Yves Douillard,Yutaka Nishiwaki,Johan Vansteenkiste,Shinzoh Kudoh,Danny Rischin,Richard Eek,Takeshi Horai,Kazumasa Noda,Ichiro Takata,Egbert F. Smit,Steven D. Averbuch,Angela Macleod,A. Feyereislova,Rui Ping Dong,José Baselga +19 more
TL;DR: Gefitinib showed clinically meaningful antitumor activity and provided symptom relief as second- and third-line treatment in patients with pretreated advanced non-small-cell lung cancer.
Related Papers (5)
Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer
Masahiro Fukuoka,Seiji Yano,Giuseppe Giaccone,Tomohide Tamura,Kazuhiko Nakagawa,Jean-Yves Douillard,Yutaka Nishiwaki,Johan Vansteenkiste,Shinzoh Kudoh,Danny Rischin,Richard Eek,Takeshi Horai,Kazumasa Noda,Ichiro Takata,Egbert F. Smit,Steven D. Averbuch,Angela Macleod,A. Feyereislova,Rui Ping Dong,José Baselga +19 more
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J. Guillermo Paez,Pasi A. Jänne,Pasi A. Jänne,Jeffrey C. Lee,Sean Tracy,Heidi Greulich,Heidi Greulich,Stacey Gabriel,Paula Herman,Frederic J. Kaye,Neal I. Lindeman,Titus J. Boggon,Katsuhiko Naoki,Hidefumini Sasaki,Yoshitaka Fujii,Michael J. Eck,William R. Sellers,William R. Sellers,William R. Sellers,Bruce E. Johnson,Bruce E. Johnson,Matthew Meyerson,Matthew Meyerson +22 more
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
Erlotinib in previously treated non-small-cell lung cancer.
Frances A. Shepherd,José Rodrigues Pereira,Tudor Ciuleanu,Eng Huat Tan,Vera Hirsh,Sumitra Thongprasert,Daniel Campos,Savitree Maoleekoonpiroj,Michael Smylie,Renato G. Martins,Maximiliano Van Kooten,Mircea Dediu,B. Findlay,Dongsheng Tu,Dianne Johnston,Andrea Bezjak,Gary M. Clark,Pedro Santabárbara,Lesley Seymour +18 more